B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases

嵌合抗原受体 受体 医学 免疫学 病毒学 T细胞 免疫系统 内科学
作者
Aiden Haghikia,Georg Andreas Schett,Dimitrios Mougiakakos
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:23 (6): 615-624 被引量:92
标识
DOI:10.1016/s1474-4422(24)00140-6
摘要

BACKGROUND: Neuroimmunology research and development has been marked by substantial advances, particularly in the treatment of neuroimmunological diseases, such as multiple sclerosis, myasthenia gravis, neuromyelitis optica spectrum disorders, and myelin oligodendrocyte glycoprotein antibody disease. With more than 20 drugs approved for multiple sclerosis alone, treatment has become more personalised. The approval of disease-modifying therapies, particularly those targeting B cells, has highlighted the role of immunotherapeutic interventions in the management of these diseases. Despite these successes, challenges remain, particularly for patients who do not respond to conventional therapies, underscoring the need for innovative approaches. RECENT DEVELOPMENTS: The approval of monoclonal antibodies, such as ocrelizumab and ofatumumab, which target CD20, and inebilizumab, which targets CD19, for the treatment of various neuroimmunological diseases reflects progress in the understanding and management of B-cell activity. However, the limitations of these therapies in halting disease progression or activity in patients with multiple sclerosis or neuromyelitis optica spectrum disorders have prompted the exploration of cell-based therapies, particularly chimeric antigen receptor (CAR) T cells. Initially successful in the treatment of B cell-derived malignancies, CAR T cells offer a novel therapeutic mechanism by directly targeting and eliminating B cells, potentially overcoming the shortcomings of antibody-mediated B cell depletion. WHERE NEXT?: The use of CAR T cells in autoimmune diseases and B cell-driven neuroimmunological diseases shows promise as a targeted and durable option. CAR T cells act autonomously, penetrating deep tissue and effectively depleting B cells, especially in the CNS. Although the therapeutic potential of CAR T cells is substantial, their application faces hurdles such as complex logistics and management of therapy-associated toxic effects. Ongoing and upcoming clinical trials will be crucial in determining the safety, efficacy, and applicability of CAR T cells. As research progresses, CAR T cell therapy has the potential to transform treatment for patients with neuroimmunological diseases. It could offer extended periods of remission and a new standard in the management of autoimmune and neuroimmunological disorders.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
俭朴大碗发布了新的文献求助10
刚刚
今后的应助被冲冲采纳,获得10
刚刚
刚刚
标致哑铃完成签到,获得积分10
1秒前
1秒前
renn发布了新的文献求助20
1秒前
2秒前
沐木发布了新的文献求助10
3秒前
水弘的应助被怕孤独的白容采纳,获得10
3秒前
老班长发布了新的文献求助10
3秒前
3秒前
白鸿完成签到,获得积分10
4秒前
1111111完成签到,获得积分20
4秒前
俭朴大碗完成签到,获得积分10
5秒前
记忆面包完成签到,获得积分10
5秒前
6秒前
牧百川发布了新的文献求助10
6秒前
牧百川发布了新的文献求助10
6秒前
7秒前
万能图书馆的应助被邹广浩采纳,获得30
7秒前
APIU发布了新的文献求助10
7秒前
tlc_191026发布了新的文献求助10
8秒前
8秒前
8秒前
谢逸杰完成签到 ,获得积分10
9秒前
9秒前
9秒前
牧百川发布了新的文献求助10
9秒前
牧百川发布了新的文献求助10
9秒前
华仔的应助被1097采纳,获得10
9秒前
牧百川发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
牧百川发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183449
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827509
捐赠科研通 7780646
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480371